Table 1.
Bioinformatic analysis of bibliographic systematic review
| MeSH | t+ | t− | b+ | b− | WholeSize | t-Ratio | b-Ratio | t-ratio/b-ratio | P-value |
|---|---|---|---|---|---|---|---|---|---|
| Angiogenesis inhibitors | 33 | 149 | 8120 | 19,435,023 | 19,443,143 | 0.18 | 4.18E-04 | 434.2 | 6.18E-76 |
| Neovascularization, pathologic | 31 | 151 | 22,709 | 19,420,434 | 19,443,143 | 0.17 | 1.17E-03 | 145.8 | 9.89E-57 |
| Vascular endothelial growth factor A | 18 | 164 | 20,847 | 19,422,296 | 19,443,143 | 0.1 | 1.07E-03 | 92.2 | 9.41E-30 |
| Thalidomide | 12 | 170 | 4628 | 19,438,515 | 19,443,143 | 0.07 | 2.38E-04 | 277 | 6.17E-26 |
| Herpesvirus 8, human | 9 | 173 | 3009 | 19,440,134 | 19,443,143 | 0.05 | 1.55E-04 | 319.5 | 2.49E-20 |
| Macular degeneration | 7 | 175 | 7925 | 19,435,218 | 19,443,143 | 0.04 | 4.08E-04 | 94.4 | 2.06E-12 |
| von Hippel–Lindau disease | 5 | 177 | 1744 | 19,441,399 | 19,443,143 | 0.03 | 8.97E-05 | 306.3 | 9.10E-12 |
| Lymphangioleiomyomatosis | 4 | 178 | 569 | 19,442,574 | 19,443,143 | 0.02 | 2.93E-05 | 751 | 3.29E-11 |
| Endothelial cells | 7 | 175 | 15,420 | 19,427,723 | 19,443,143 | 0.04 | 7.93E-04 | 48.5 | 2.05E-10 |
| Carcinoma, renal cell | 7 | 175 | 16,035 | 19,427,108 | 19,443,143 | 0.04 | 8.25E-04 | 46.6 | 2.68E-10 |
| Exudates and transudates | 6 | 176 | 8354 | 19,434,789 | 19,443,143 | 0.03 | 4.30E-04 | 76.7 | 2.75E-10 |
| Hypoxia-inducible factor 1, alpha subunit | 5 | 177 | 4123 | 19,439,020 | 19,443,143 | 0.03 | 2.12E-04 | 129.6 | 6.57E-10 |
| Vascular malformations | 3 | 179 | 311 | 19,442,832 | 19,443,143 | 0.02 | 1.60E-05 | 1030.5 | 4.11E-09 |
| Telangiectasia, hereditary hemorrhagic | 4 | 178 | 1929 | 19,441,214 | 19,443,143 | 0.02 | 9.92E-05 | 221.5 | 4.25E-09 |
| Activin receptors, type II | 3 | 179 | 346 | 19,442,797 | 19,443,143 | 0.02 | 1.78E-05 | 926.3 | 5.65E-09 |
| Hemangioendothelioma, epithelioid | 3 | 179 | 459 | 19,442,684 | 19,443,143 | 0.02 | 2.36E-05 | 698.2 | 1.31E-08 |
| Vascular endothelial growth factors | 5 | 177 | 7692 | 19,435,451 | 19,443,143 | 0.03 | 3.96E-04 | 69.4 | 1.44E-08 |
| Angiogenic proteins | 3 | 179 | 482 | 19,442,661 | 19,443,143 | 0.02 | 2.48E-05 | 664.9 | 1.52E-08 |
| POEMS syndrome | 3 | 179 | 486 | 19,442,657 | 19,443,143 | 0.02 | 2.50E-05 | 659.4 | 1.56E-08 |
| Osteolysis, essential | 3 | 179 | 541 | 19,442,602 | 19,443,143 | 0.02 | 2.78E-05 | 592.4 | 2.15E-08 |
| Hemangioma, capillary | 3 | 179 | 665 | 19,442,478 | 19,443,143 | 0.02 | 3.42E-05 | 481.9 | 3.97E-08 |
| Protein kinase inhibitors | 5 | 177 | 10,840 | 19,432,303 | 19,443,143 | 0.03 | 5.58E-04 | 49.3 | 7.82E-08 |
| Interferon-alpha | 5 | 177 | 11637 | 19,431,506 | 19,443,143 | 0.03 | 5.99E-04 | 45.9 | 1.11E-07 |
| Pyrroles | 5 | 177 | 11,893 | 19,431,250 | 19,443,143 | 0.03 | 6.12E-04 | 44.9 | 1.23E-07 |
| Von Hippel–Lindau tumor suppressor protein | 3 | 179 | 1082 | 19,442,061 | 19,443,143 | 0.02 | 5.56E-05 | 296.2 | 1.70E-07 |
| Hypoxia-inducible factor 1 | 3 | 179 | 1746 | 19,441,397 | 19,443,143 | 0.02 | 8.98E-05 | 183.6 | 7.10E-07 |
| Endothelial growth factors | 4 | 178 | 7866 | 19,435,277 | 19,443,143 | 0.02 | 4.05E-04 | 54.3 | 1.12E-06 |
| Sarcoma, kaposi | 4 | 178 | 8163 | 19,434,980 | 19,443,143 | 0.02 | 4.20E-04 | 52.3 | 1.30E-06 |
| Linkage disequilibrium | 4 | 178 | 8690 | 19,434,453 | 19,443,143 | 0.02 | 4.47E-04 | 49.2 | 1.66E-06 |
| Rare diseases | 3 | 179 | 2370 | 19,440,773 | 19,443,143 | 0.02 | 1.22E-04 | 135.2 | 1.77E-06 |
| Collagen type XVIII | 2 | 180 | 202 | 19,442,941 | 19,443,143 | 0.01 | 1.04E-05 | 1057.7 | 1.80E-06 |
| Receptors, vascular endothelial growth factor | 3 | 179 | 2497 | 19,440,646 | 19,443,143 | 0.02 | 1.28E-04 | 128.4 | 2.06E-06 |
| Lipoid proteinosis of urbach and wiethe | 2 | 180 | 246 | 19,442,897 | 19,443,143 | 0.01 | 1.27E-05 | 868.5 | 2.67E-06 |
| Retinal vessels | 4 | 178 | 9999 | 19,433,144 | 19,443,143 | 0.02 | 5.14E-04 | 42.7 | 2.88E-06 |
| Stem cell transplantation | 4 | 178 | 10,093 | 19,433,050 | 19,443,143 | 0.02 | 5.19E-04 | 42.3 | 2.99E-06 |
| Receptors, CXCR4 | 3 | 179 | 3315 | 19,439,828 | 19,443,143 | 0.02 | 1.70E-04 | 96.7 | 4.80E-06 |
| Dacarbazine | 3 | 179 | 3542 | 19,439,601 | 19,443,143 | 0.02 | 1.82E-04 | 90.5 | 5.84E-06 |
MeSH, medical subject headings; t+, number of papers annotated with the MeSH in the sample PMIDs; t−, number of papers not annotated with the MeSH in the sample PMIDs; b+, number of papers annotated with the MeSH in whole PMIDs; b−, number of papers not annotated with the MeSH in whole PMIDs; WholeSize, whole PMIDs; t-ratio, proportion in the sample PMIDs; b-ratio, proportion in the whole PMIDs; t-ratio/b-ratio, value relative to the enrichment of the MeSH term; and P-value, Hypergeometric test value.